1月30日，罗氏发布2024年财报，全年营收604.95亿瑞士法郎（约688.92亿美元，按2024年平均汇率换算：1瑞士法郎=1.1388美元），同比增长7%（按固定汇率CER计算）；研发投入130.42亿瑞士法郎（约148.52亿美元），约占总营 ...

Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B-cells (an immune cell impacted in some types of non-Hodgkin ...

Minjuvi's closest rival is actually Roche's antibody-drug conjugate Polivy (polatuzumab vedotin), which was approved for DLBCL in the EU last year but targets the CD79b receptor. Incyte and ...

After hours: January 31 at 6:49:29 PM EST Loading Chart for MGNX ...

Correspondence to Professor Guy Boeckxstaens, Translational Research in Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing (Chrometa), KU Leuven, Leuven, ...